Announcements Trials
Browse Landscape

Phase

Phase 2 153Phase 1 32Phase 1/2 29Phase 3 20Phase NA 5Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 3

Status

Completed 13Recruiting 10Active not recruiting 5Unknown 3Terminated 3Not yet recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2NET 1Endocrine 1CNS 1

Conditions

Vipoma 1Somatostatinoma 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Glioblastoma 1Gastrinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Astrocytoma 1Adenoma, Islet Cell 1

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Bevacizumab × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated
403 enrolled
CNS

Astrocytoma, Glioblastoma, Recurrence

NCT01383148 2017-01-05

TIME

Transgene

Phase 2/3 Terminated
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡